Northpointe Capital LLC Has $15,442,000 Stake in Novavax Inc. (NVAX)
Northpointe Capital LLC raised its stake in Novavax Inc. (NASDAQ:NVAX) by 47.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,124,035 shares of the biopharmaceutical company’s stock after buying an additional 681,133 shares during the period. Novavax comprises approximately 1.8% of Northpointe Capital LLC’s holdings, making the stock its 3rd largest position. Northpointe Capital LLC owned 0.78% of Novavax worth $15,442,000 as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. BlackRock Inc. boosted its position in shares of Novavax by 138.7% in the first quarter. BlackRock Inc. now owns 19,870 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 11,547 shares in the last quarter. IFP Advisors Inc boosted its position in shares of Novavax by 1.7% in the first quarter. IFP Advisors Inc now owns 28,296 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 480 shares in the last quarter. Parametrica Management Ltd boosted its position in shares of Novavax by 43.1% in the second quarter. Parametrica Management Ltd now owns 29,760 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 8,960 shares in the last quarter. Barclays PLC boosted its position in shares of Novavax by 202.8% in the first quarter. Barclays PLC now owns 53,215 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 35,640 shares in the last quarter. Finally, Edge Wealth Management LLC boosted its position in shares of Novavax by 9.5% in the second quarter. Edge Wealth Management LLC now owns 82,370 shares of the biopharmaceutical company’s stock valued at $599,000 after buying an additional 7,150 shares in the last quarter. 79.84% of the stock is currently owned by institutional investors.
Novavax Inc. (NASDAQ:NVAX) remained flat at $2.08 during mid-day trading on Monday. 11,253,599 shares of the company were exchanged. The stock has a 50-day moving average price of $5.65 and a 200-day moving average price of $6.01. Novavax Inc. has a one year low of $1.16 and a one year high of $9.23. The stock’s market capitalization is $563.33 million.
Novavax (NASDAQ:NVAX) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.04. Novavax had a negative return on equity of 112.45% and a negative net margin of 1,405.84%. The business had revenue of $2.50 million for the quarter, compared to the consensus estimate of $8.03 million. During the same period in the previous year, the company posted ($0.08) earnings per share. Novavax’s revenue for the quarter was down 82.1% compared to the same quarter last year. On average, equities analysts anticipate that Novavax Inc. will post ($1.09) EPS for the current year.
NVAX has been the topic of several analyst reports. Zacks Investment Research raised shares of Novavax from a “sell” rating to a “hold” rating in a research report on Friday, June 10th. Chardan Capital dropped their target price on shares of Novavax from $5.75 to $1.50 and set a “neutral” rating on the stock in a research report on Tuesday, September 20th. Piper Jaffray Cos. downgraded shares of Novavax from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $14.00 to $1.00 in a research report on Friday, September 16th. Vetr upgraded shares of Novavax from a “buy” rating to a “strong-buy” rating and set a $8.35 price target for the company in a report on Wednesday, July 13th. Finally, Wedbush cut shares of Novavax from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $14.00 to $2.00 in a report on Friday, September 16th. Seven investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $7.06.
In other Novavax news, SVP John Trizzino bought 46,000 shares of the stock in a transaction that occurred on Thursday, September 22nd. The stock was acquired at an average cost of $2.17 per share, with a total value of $99,820.00. Following the purchase, the senior vice president now owns 85,564 shares in the company, valued at $185,673.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael A. Mcmanus, Jr. bought 30,000 shares of the stock in a transaction that occurred on Wednesday, September 21st. The shares were acquired at an average cost of $1.61 per share, with a total value of $48,300.00. Following the completion of the purchase, the director now owns 247,590 shares in the company, valued at approximately $398,619.90. The disclosure for this purchase can be found here. Corporate insiders own 3.50% of the company’s stock.
Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Stock Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related stocks with our FREE daily email newsletter.